Cited by 567Neuroscience and Neuropharmacology ResearchUbiquitin and proteasome pathwaysGenetics and Neurodevelopmental Disorders

Ubiquitination Regulates PSD-95 Degradation and AMPA Receptor Surface Expression

Open access
Colledge, Marcie, Snyder, Eric M., Crozier, Robert A., Soderling, Jacquelyn A., Jin, Yetao, Langeberg, Lorene K., Lu, Hua, Bear, Mark F. +1 more·2003·Neuron

Abstract

PSD-95 is a major scaffolding protein of the postsynaptic density, tethering NMDA- and AMPA-type glutamate receptors to signaling proteins and the neuronal cytoskeleton. Here we show that PSD-95 is regulated by the ubiquitin-proteasome pathway. PSD-95 interacts with and is ubiquitinated by the E3 ligase Mdm2. In response to NMDA receptor activation, PSD-95 is ubiquitinated and rapidly removed from synaptic sites by proteasome-dependent degradation. Mutations that block PSD-95 ubiquitination prevent NMDA-induced AMPA receptor endocytosis. Likewise, proteasome inhibitors prevent NMDA-induced AMPA receptor internalization and synaptically induced long-term depression. This is consistent with the notion that PSD-95 levels are an important determinant of AMPA receptor number at the synapse. These data suggest that ubiquitination of PSD-95 through an Mdm2-mediated pathway is critical in regulating AMPA receptor surface expression during synaptic plasticity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0896-6273(03)00687-1

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GluA1 phosphorylation directly regulates trafficking, but there are other phosphatase substrates, including PSD-95 and Stargazin, that are also involved in synaptic AMPAR removal during LTD.

    “GluA1 phosphorylation directly regulates trafficking, but there are other phosphatase substrates, including PSD-95 and Stargazin, that are also involved in synaptic AMPAR removal during LTD.”

    From AKAP150-Anchored Calcineurin Regulates Synaptic Plasticity by Limiting Synaptic Incorporation of Ca<sup>2+</sup>-Permeable AMPA Receptors (2012) · cites this paper as Colledge et al., 2003

    The Discussion and the section on PSD-95 ubiquitination link PSD-95 to NMDA-induced AMPA receptor removal, and the paper reports that proteasome inhibitors block LTD (page numbers unavailable). It suggests PP2B may participate in PSD-95 degradation, but does not establish PSD-95 as a direct phosphatase substrate; the Introduction mentions stargazin in AMPA receptor targeting, not as a phosphatase substrate involved in receptor removal during LTD. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • NMDA-cLTD activation of CaN and PP1/2A negatively regulates PSD-95 postsynaptic clustering and binding to Stargazin to promote AMPAR removal.

    “In particular, NMDA-cLTD activation of CaN and PP1/2A negatively regulates PSD-95 postsynaptic clustering and binding to Stargazin to promote AMPAR removal”

    From AKAP150-Anchored Calcineurin Regulates Synaptic Plasticity by Limiting Synaptic Incorporation of Ca<sup>2+</sup>-Permeable AMPA Receptors (2012) · cites this paper as Colledge et al., 2003

    The Discussion reports that NMDA receptor activation triggers PSD-95 ubiquitination and removal from synaptic sites, potentially allowing AMPA receptor endocytosis. The paper also reports that inhibiting PP2B (calcineurin) prevents NMDA-induced PSD-95 loss, and the Introduction notes that PSD-95 binds stargazin. It does not show that PP1/PP2A mediate this process or that NMDA stimulation reduces PSD-95’s binding to stargazin. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [2]2. Bear, M.F. ∙ Malenka, R.C. Synaptic plasticityLTP and LTD Curr. Opin. Neurobiol. 1994; 4:389-399 Crossref Scopus (1098) PubMed Google Scholar

Cited by

Sorted by citations

Authors
Colledge, M., Snyder, E. M., Crozier, R. A., Soderling, J. A., Jin, Y., Langeberg, L. K., Lu, H., Bear, M. F., & Scott, J. D.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Oregon Health & Science University (US)
Corresponding author
Scott, John D.
Venue
Neuron
Publisher
Elsevier BV
Published
2003-10
Volume
40
Issue
3
Pages
595-607
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2151538478
Cited by
567
References
65
Citations by year
2026: 8 · 2025: 16 · 2024: 20 · 2023: 11 · 2022: 12 · 2021: 24 · 2020: 20 · 2019: 23 · 2018: 18 · 2017: 21 · 2016: 20 · 2015: 36 · 2014: 22 · 2013: 30 · 2012: 26
FWCI
9.49
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of General Medical Sciences (R01GM048231, GM-48231, R37GM048231)
  • National Institute of Neurological Disorders and Stroke (NS 39321, P01NS039321)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
PSD-95, ubiquitination, MDM2, proteasomal degradation, AMPA receptors, receptor internalization, NMDA receptor activation, postsynaptic density, synaptic plasticity, long-term depression, glutamate receptors
MeSH terms
Disks Large Homolog 4 Protein, Acetylcysteine, Analysis of Variance, Animals, Animals, Newborn, Epitopes, Calcium, Cells, Cultured, Drug Interactions, Electric Stimulation, Embryo, Mammalian, Endocytosis, Colforsin, Hippocampus, Humans, Immunoglobulin G, Immunohistochemistry, Immunosuppressive Agents, Kidney, Leupeptins, Membrane Potentials, Membrane Proteins, Mutation, Nerve Tissue Proteins, Neural Inhibition, Neurons, Nuclear Proteins, Proto-Oncogene Proteins, Synapses, Time Factors, Transfection, Blotting, Western, Cysteine Proteinase Inhibitors, N-Methylaspartate, Tacrolimus, Synapsins, Receptors, AMPA, Patch-Clamp Techniques, Excitatory Amino Acid Agonists, Rats, Long-Evans, Ubiquitin, Intracellular Signaling Peptides and Proteins, Rats, Proto-Oncogene Proteins c-mdm2, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review